Skip to content

Targon PH+ Follow-Up

Prospective Cohort Study of Proximal Humeral Fractures Treated With Targon® PH+

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02836366
Enrollment
50
Registered
2016-07-19
Start date
2016-03-31
Completion date
2019-04-30
Last updated
2019-06-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Shoulder Fractures

Keywords

Proximal humerus, Fracture, Nailing

Brief summary

With this study results of the Targon® PH+ nail, developed for the treatment of humeral head fractures, will be investigated clinically, radiological evaluation is optional. The primary objective of this study is to examine the effect of a plating treatment on the speed of recovery of functional capacity in adult patients. Secondary aims are to examine the level of pain, patient satisfaction, shoulder function, quality of life, radiological evaluation and complications. Targon PH+ is CE certified. The study is a non-interventional cohort study sponsored by Aesculap

Interventions

None listed

Sponsors

Aesculap AG
Lead SponsorINDUSTRY

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
60 Years to No maximum
Healthy volunteers
No

Inclusion criteria

- patients with a three- or four-fragment-fracture of the proximal humerus, with dislocation on X-ray * older than 60 years of age * written and signed patient consent

Exclusion criteria

- Fractures more than 14 days old * multiple comorbidity * multitrauma (Injury Severity Score \> 15) * prev. surgery on the injured shoulder * severely deranged function caused by a previous disease head-split proximal humerus fracture * combined humerus head and shaft fractures * pseudarthroses * crushed head cap of the humerus head (AO 11 C3 fractures) * isolated avulsion fracture of a tuberosity * unwillingness or inability to follow protocol instructions and study requirements (follow-up visits) * no signed informed consent * treatment not in line with Instructions for Use (IfU)

Design outcomes

Primary

MeasureTime frameDescription
Functional Capacity24 monthsThe DASH score (Disabilities of the Arm, Shoulder, and Hand) will be used to determine the recovery of functional capacity. It provides a summary of the responses on a scale of 0 (no disability) to 100 (severe disability)

Secondary

MeasureTime frameDescription
Level of pain3, 12 and 24 months10-point Visual Analogue Scale (VAS) from no pain (0) to most extreme pain imaginable (10)
Patient satisfaction24 months4 point scale: very satisfied, satisfied, unsatisfied, very unsatisfied
Shoulder Function12 months, 24 monthsShoulder function outcome is measured with the Constant-Murley score, this score system combines shoulder function tests (65 points) with a subjective evaluation of the patients (35 points) including activities of daily living, level of work
Radiological outcome (only if it could be raised in clinical standard)24 monthsThe X-rays are examined regarding adverse events as screw perforation, screw breakage, cut-out, re-dislocation of the fracture
Adverse Events24 monthsRate of Adverse Events, for example secondary interventions (revisions) that occur within the follow-up period

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026